Company intelligence / Profile preview
InnovoTEX
Austin, Texas, United Statesinnovotexinc.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
INNOVOTEX is developing a proprietary macrocycle-mediated drug delivery platform for targeted cancer therapy. Their approach enables precise delivery of therapeutics to solid tumors, including those that are aggressive or resistant to current treatments. The technology has been clinically de-risked by leveraging a macrocycle core previously used in over 1000 patients. The company has announced breakthrough data presentations at major oncology conferences but does not yet have commercial-stage products[1][3].
- Therapeutic areas
- Oncology
- Modalities
- Macrocycle drug conjugates (MDCs)Multi-modal payloads (implied to include small molecules and possibly other therapeutic agents)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on InnovoTEX.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InnovoTEX.